Micreos develops targeted antibacterial solutions based on endolysin- and phage-technology to deliver precision antibacterials and replace broad-spectrum antibiotics. Its product portfolio includes consumer brand Gladskin, which last year helped hundreds of thousands of people in Europe and the USA, and pharmaceutical programs advancing endolysins against staphylococci, including MRSA. Clinical indications being pursued include bloodstream infections, atopic dermatitis, diabetic foot ulcers and cutaneous T‑cell lymphoma. The company recently restructured to separate its Pharmaceutical business from its OTC Consumer Health business to enable each to pursue tailored growth strategies. Micreos also markets PhageGuard food‑safety products for food processors and maintains a long-term collaboration with ETH Zürich. Headquarters and operations are distributed across The Hague (head office), Zug (Micreos Pharmaceuticals HQ), Wädenswil (Discovery & Technology Center), Bilthoven (Development Team) and Gladskin offices in the USA, Germany, France and the UK. Micreos develops biological therapies built on proprietary endolysin technology created together with ETH Zurich, focused on targeted killing of only unwanted bacteria. Its pharmaceutical lead compounds are XZ.700, which targets Staphylococcus aureus including MRSA while preserving beneficial Staphylococcus epidermidis, and SP.800, which targets all staphylococcal species. The company is led by founder and CEO Mark Offerhaus and operates a technology center in Zurich with additional operations in the Netherlands and the USA. Under the Gladskin brand Micreos has launched several endolysin-based OTC products for inflammatory skin conditions and has helped hundreds of thousands of people. The company is advancing clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections based on its lead compounds. Recent fundraising is intended to accelerate those clinical development efforts. Micreos develops antibacterial solutions based on phage technology and lysins as replacements for antibiotics across healthcare, veterinary, food processing and agriculture. The company will use the €12m equity funding for global development of Staphefekt™ as a pharmaceutical (Rx) product. Staphefekt™ was launched in 2013 as the active lysin compound in Gladskin for inflammatory skin conditions such as eczema, rosacea and acne. Micreos also markets FDA-approved food safety products, including LISTEX™ (Listeria) and SALMONELEX™ (Salmonella), sold globally to meat & poultry, cheese and fish processors. The company operates production facilities in Wageningen and Bilthoven and has a long-term cooperation with ETH Zurich. Micreos is led by CEO Mark Offerhaus. Micreos develops phage-based products targeting dangerous bacteria, with a primary focus on antibacterial solutions for human health and food safety. The company is led by CEO Mark Offerhaus and is based in Wageningen, The Netherlands. It raised additional capital through a strategic investment in which Altria Ventures acquired a 5% stake. The amount of the funding was not disclosed. Micreos intends to use the funding to accelerate the growth of its phage business and expand its commercial efforts.

Total raised

$75M

Funding rounds

4

Latest round

Equity

Latest activity

Oct 2022